Hot Flashes and Night Sweats – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Hot Flashes and Night Sweats Market Outlook

Thelansis’s “Hot Flashes and Night Sweats Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hot Flashes and Night Sweats treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Hot Flashes and Night Sweats Overview

Hot Flashes and Night Sweats are significant symptoms that occur in most women across the globe. A woman with Vasomotor Symptoms experiences much heat accompanied by sweating and flushing, especially around the head, neck, chest, and upper back region. These are the menopausal symptoms for which women seek treatment most often during menopause. VMS results from temperature dysfunction that occurs due to changes in gonadal hormones. 60-80% of women experience VMS during the menopausal transition, with prevalence rates varying by racial/ethnic group. One of the well-known symptoms of menopause is the occurrence of hot flashes, which occur in >75% of menopausal women. Hot flashes are often described as episodic sensations of heat, intense sweating, and flushing affecting the face and chest, often accompanied by palpitations and anxiety. Each episode lasts 3–10 minutes, and attacks can recur with varying frequency. Some women encounter hot flashes hourly or daily, whereas, for others, they may occur occasionally. The age at onset of hot flashes is hypothesized to be involving pathology of the thermoregulatory nucleus that is crucial in controlling the homeostatic condition and, therefore, the core body temperature. The thermoregulatory nucleus maintains the core temperature within the intervals of physiological needs, termed a thermoregulatory zone.

• The prevalence of Hot Flashes and Night Sweats varies from 14,560 to 16,500 per 100,000 population in the USA.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: